Loading...
Market
What will be the market share of Sasanlimab in high-risk NMIBC treatments by end of 2026?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Industry reports and market analysis
Story
Pfizer's Phase 3 Study Shows Sasanlimab with BCG Improves Event-Free Survival in High-Risk Non-Muscle Invasive Bladder Cancer
Jan 10, 2025, 11:52 AM
Pfizer has announced positive topline results from its Phase 3 study indicating that Sasanlimab, when combined with Bacillus Calmette-Guérin (BCG), improves event-free survival in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The study met its primary endpoint as assessed by investigators. Pfizer also reported that the safety profile of Sasanlimab was consistent with previous findings, suggesting a favorable outcome for this treatment approach in a challenging patient population.
View original story
Similar markets
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Less than 10% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
Third • 25%
Leading • 25%
Lower • 25%
Second • 25%
5% to 10% • 25%
More than 15% • 25%
10% to 15% • 25%
Less than 5% • 25%
No • 50%
Yes • 50%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
20% to 40% • 25%
Less than 20% • 25%
More than 60% • 25%
40% to 60% • 25%
Yes • 50%
No • 50%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 20% • 25%
20% to 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
More than 30% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
30% to 50% • 25%
More than 50% • 25%
10% to 30% • 25%